H.B. Fuller Company (FUL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
4 Mar, 2026Executive summary
The 2026 Annual Meeting will be held virtually on April 16, 2026, with shareholders able to vote and submit questions electronically.
Key business includes electing three directors, ratifying the appointment of Ernst & Young LLP as auditor, and a non-binding advisory vote on executive compensation.
2025 financial highlights: net revenue of $3.47B, net income of $152M, adjusted EPS of $4.24, adjusted EBITDA of $621M, and a 5.6% increase in quarterly dividends.
The company continued to focus on higher-margin, faster-growing segments and delivered record adjusted EBITDA margin of 17.9%.
Voting matters and shareholder proposals
Shareholders will vote on the election of three Class III directors for terms expiring in 2029.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 is up for shareholder approval.
Advisory vote on executive compensation (Say on Pay) is included, with prior year support at 97%.
Board of directors and corporate governance
Board consists of nine directors in three classes, with a strong emphasis on diversity: 56% women, 11% ethnically/racially diverse, and 89% independent.
Board committees include Audit, Compensation, and Corporate Governance and Nominating, all chaired by independent directors.
Annual board and committee performance evaluations are conducted, and a code of business conduct applies to all directors and employees.
Shareholder recommendations for director nominees are considered using established criteria for diversity and experience.
Latest events from H.B. Fuller Company
- Q3 2024 saw 6% EBITDA and 7% EPS growth, led by strong Construction Adhesives results.FUL
Q3 20249 Jul 2026 - Adjusted EBITDA and EPS rose with margin expansion despite a 6.6% organic revenue decline.FUL
Q1 20268 Jul 2026 - Adjusted EBITDA and EPS grew 5% year-over-year, with margin gains and raised full-year guidance.FUL
Q2 20258 Jul 2026 - Q2 2026 saw strong revenue, margin, and EPS growth, with a major medical acquisition announced.FUL
Q2 202625 Jun 2026 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.FUL
AGM 202616 Apr 2026 - Votes will be cast for director elections, auditor ratification, and executive pay approval.FUL
Proxy Filing4 Mar 2026 - Adjusted EPS up 20% and EBITDA up 10% year-over-year, with 2024 guidance raised.FUL
Q2 20243 Feb 2026 - Margin and EPS growth achieved through cost actions and acquisitions despite revenue headwinds.FUL
Q4 202515 Jan 2026 - FY24 revenue up 1.6%, margin at 16.6%; 2025 outlook cautious with cost and footprint actions.FUL
Q4 202410 Jan 2026